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Original Article
Systemic blood pressure trends and antihypertensive 
utilization following continuous-flow left ventricular assist 
device implantation: an analysis of the interagency registry for 
mechanically assisted circulatory support
Adham Elmously1, Andreas R. de Biasi1, Donald A. Risucci2,3, Berhane Worku1, Evelyn M. Horn4, 
Arash Salemi1
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Background: Elevated systemic blood pressure (SBP) has been linked to complications in Continuous-flow 
left ventricular assist devices (CF-LVADs), including stroke and pump thrombosis. We queried Interagency 
Registry for Mechanically Assisted Circulatory Support (INTERMACS) to describe the response of SBP 
to CF-LVAD implantation and to delineate contemporary trends in antihypertensive (AH) utilization for 
patients with these pumps. 
Methods: We identified all CF-LVAD implantations in patients older than 18 years from 2006–
2014, excluding those whose durations were less than 30 days. Pre-implant patient demographics and 
characteristics were obtained for each record. SBPs [i.e., mean arterial pressures (MAPs)], AH-use data, and 
vital status were tabulated, extending up to 5 years following implantation. 
Results: A total of 10,329 CF-LVAD implantations were included for study. Post-implant, SBPs increased 
rapidly during the first 3 months but plateaued thereafter; AH utilization mirrored this trend. By 6 months, 
mean MAPs climbed 12.2% from 77.6 mmHg (95% CI: 77.4–77.8) pre-implantation to 87.1 mmHg (95% 
CI: 86.7–87.4) and patients required a mean of 1.8 AH medications (95% CI: 1.75–1.78) —a 125% increase 
from AH use at 1-week post-implantation (0.8 AHs/patient, 95% CI: 0.81–0.83) but a 5.3% decrease from 
pre-implant utilization (1.9 AHs/patient, 95% CI: 1.90–1.92). Once medication changes stabilized, the most 
common AH regimens were lone beta blockade (15%, n=720) and a beta blocker plus an ACE inhibitor (14%, 
n=672). 
Conclusions: SBP rises rapidly after CF-LVAD implantation, stabilizing after 3 months, and is matched 
by concomitant changes in AH utilization; this AH use has increased over consecutive implant years.
Keywords: Systemic blood pressure (SBP); antihypertensive (AH); continuous-flow (CF); left ventricular assist 
device (LVAD); Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)
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Introduction
Continuous-flow left ventricular assist devices (CF-
LVADs) have emerged as a standard treatment option for 
patients with refractory, inotrope-dependent heart failure, 
with 1- and 2-year actuarial survival rates of 80% and 
70%, respectively, for the current generation of Food and 
Drug Administration (FDA)-approved devices (1). Since 
the output from CF pumps is afterload dependent (2,3), 
systemic blood pressure (SBP) is believed to be inextricably 
linked to the performance of these LVADs and hence, 
to the clinical outcomes of the patients in which they 
are implanted (3). It has therefore been postulated that 
systemic hypertension can contribute to the risk of aortic 
insufficiency, device thrombosis, stroke, and even death in 
patients with CF devices (3-6).
However, there is little evidence in the literature to 
support such suppositions as our community has yet 
to rigorously characterize the impacts that systemic 
hypertension can have on patients with these pumps. More 
fundamentally, largely missing from our evidence base is a 
basic demonstration of how SBP changes after CF-LVAD 
implantation and further lacking are descriptions of how 
hypertension is actually being treated when encountered in 
this mode of mechanical circulatory support (MCS).
We therefore queried the Interagency Registry for 
Mechanically Assisted Circulatory Support (INTERMACS) 
in order to more clearly describe the response of SBP to 
CF-LVAD implantation and to delineate contemporary 
trends in antihypertensive (AH) management for patients 
with these life-sustaining devices.
Methods
Data source
INTERMACS was established in 2005 as a joint effort of 
the National Heart, Lung, and Blood Institute, the FDA, 
clinicians, scientists, and industry representatives; and 
is housed and maintained by the University of Alabama 
at Birmingham (7). This prospective registry collects 
clinical data on heart failure patients receiving MCS and is 
recognized as the Joint-Commission-mandated registry for 
all US centers implanting devices for destination therapy 
(DT) (7). The registry captures: pre-implant patient 
demographics and characteristics, in-hospital and procedural 
data related to MCS device implantations, as well as post-
implant follow-up information, including adverse events 
and rehospitalizations (7). INTERMACS has a Data and 
Clinical Coordinating Center (DCC) comprised of experts 
who check the data from each site for internal validity 
remotely. Sites with suspicious data or data discrepancies 
are flagged and audited. To date, INTERMACS contains 
records on upwards of 10,000 MCS device implantations, 
contributed by over 200 participating hospitals (1), making 
it the largest repository of contemporary data on MCS 
patients in the world. The registry has been used during 
device approval, in post-approval follow-up studies, and as 
a vital resource in examining many specific MCS-related 
questions (8-10).
This study conforms to the policies set forth by both 
the INTERMACS Data Access, Analysis, and Publications 
Committee and the INTERMACS Data Coordinating 
Center and was exempted from review by the Institutional 
Review Board of Weill Cornell Medical College since 
registry data are de-identified and stored in aggregate. 
This project was funded, in whole or in part, with federal 
funds from the National Heart, Lung, and Blood Institute 
of the National Institutes of Health, Department of 
Health and Human Services, under contract number 
HHSN268201100025C.
Patient population and data collection
We queried INTERMACS to identify all adult (i.e., age 
greater than 18 years) CF-LVAD implantations from 
2006 to 2014, excluding those whose durations were less 
than 30 days. Pre-implant patient demographics and 
characteristics were obtained for each of these implantation 
records, which included: age, gender, body mass index, 
primary cardiac diagnosis, comorbidities, INTERMACS 
profile, SBP, echocardiographic data, device strategy, and 
AH history. Pre-implant data is collected during the index 
hospitalization for implantation. Specifically, this data is 
collected at the time of implant or closest to the implant 
date and within 30 days of implant, but is not collected in 
the operating room.
SBPs, AH-utilization data, and vital status were then 
obtained for each of the implant records identified 
for inclusion, beginning at 1-week post-implant and 
extending up to 5 years after device implantation. It is 
important to note that AH-utilization prior to LVAD 
implantation was a representation of neurohumoral 
modulatory agent utilization as patients at this point were 
likely to be receiving therapy for heart failure and not 
exclusively for hypertension. Of note, SBPs are recorded 
in INTERMACS as either systolic/diastolic pressures or 
2868
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(5):2866-2875jtd.amegroups.com
Elmously et al. SBP trends in CF-LVADs
as single Doppler opening pressures. Herein, we express 
all systemic pressures as mean arterial pressures (MAPs), 
which were calculated using the systolic/diastolic pressures 
when only those measurements were available. If both 
systolic/diastolic and Doppler values were documented or 
when only Doppler pressures were recorded, the MAPs 
were assumed to be equal to the Doppler pressures and 
were tabulated as such.
Study objectives and statistical analyses
The objectives of this study were two-fold: (I) to 
characterize trends of the response of SBP to CF-LVAD 
implantation on a large scale and (II) to describe the trends 
in AH utilization following CF-LVAD implantation, 
examining for possible changes in medication usage by 
implant era. 
Patient demographics and characteristics as well as 
follow-up blood pressures and AH-use data were expressed 
as frequencies and percentages for categorical variables 
and as means ± standard deviations (SDs) for continuous 
variables. Categorical variables were compared using the 
Pearson chi-square test; all P values were two-sided with 
statistical significance evaluated at the 0.05 α level. No 
missing-values estimations were performed, as only data 
that were available at a given time point were reported. 
Statistical analyses were performed using SPSS Version 19 
(IBM Corp., Armonk, NY, USA) and Excel 2013 (Microsoft 
Corp., Redmond, WA, USA).
Results
Patient demographics and characteristics
Over the course of the study period, the rate of CF-
LVAD implantation increased annually (Figure 1). A total 
of 10,329 CF-LVAD implantations were included for 
study. Table 1 summarizes the demographics and pre-
implantation characteristics of the patients representing 
this cohort. A plurality of implantations (32.4%, n=3,346) 
occurred during the seventh decade of life and most were 
in males (78.6%, n=8,121). Ischemic heart disease was the 
most common primary cardiac diagnosis (40.5%, n=4,178) 
within the cohort; 35.1% (n=1,686) of implantations 
were in patients with smoking histories, while upwards 
of 20% were in patients with chronic renal disease and/
or pulmonary hypertension (21.2%, n=1,021; 24.1%, 
n=1,157, respectively). The mean MAP prior to CF-LVAD 
implantation was 77.6±11.2 mmHg; on average, patients 
required 1.9±1.0 AHs. Three-quarters of implantations 
occurred in patients on beta blockers (75.8%, n=7,827) and 
nearly half occurred in those on aldosterone antagonists 
(50.6%, n=5,221) and/or angiotensin-converting-enzyme 
(ACE) inhibitors (47.8%, n=4,939).
SBP response to CF-LVAD implantation
Figure 2 depicts the response of SBP to CF-LVAD 
implantation (black line, left axis). SBPs increased rapidly 
over the first three post-implant months but plateaued 
thereafter; by 6 months, the mean MAP had increased 
to 87.1 mmHg (95% CI: 86.7–87.4), a 12.2%-increase 
from pre-implantation (77.6 mmHg, 95% CI: 77.4–77.8). 
Stratifying this blood pressure response by annual survival 
revealed that systemic pressures, after reaching a plateau, 
fell precipitously within the year preceding death (Figure 3).
AH utilization following CF-LVAD implantation
Overal l  AH requirements  increased af ter  device 
implantation, as also illustrated by Figure 2 (grey bars, right 
axis). Similar to the trend seen for SBP response, the mean 
number of AHs used quickly rose following implantation 
but leveled-off after 3 months (Figure 2). At 6 months, 
patients required a mean of 1.8 (95% CI: 1.75–1.78) AH 
medications, which represents a 125% increase from AH 
use at 1-week post-implantation (0.8 AHs/patient, 95% CI: 
0.81–0.83) but a 5.3% decrease from pre-implant utilization 
(1.9 AHs/patient, 95% CI: 1.90–1.92). By 2 years, the mean 
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Figure 1 LVADs implanted annually in the INTERMACS 
registry. The 2014 year is not included in this figure as only data 
from the first quartile of 2014 is available for this study. CF-LVAD, 
continuous flow left ventricular assist device; INTERMACS, 
Interagency Registry for Mechanically Assisted Circulatory 
Support. 
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Table 1 Patient demographics and characteristics prior to 
continuous-flow left ventricular assist device implantation
Baseline characteristics Number (%)
Total number 10,329
Age (years)
19–29 508 (4.9)
30–39 778 (7.5)
40–49 1,514 (14.7)
50–59 2,828 (27.4)
60–69 3,346 (32.4)
70–79 1,286 (12.5)
80+ 69 (0.7)
Male 8,121 (78.6)
BMI (kg/m
2
), mean ± SD 28.9±6.8
Primary cardiac diagnosis
Ischemic heart disease 4,178 (40.5)
Dilated cardiomyopathy 3,216 (31.1)
Other 2,935 (28.4)
Comorbidities
Chronic renal disease 1,021 (21.2)
Pulmonary hypertension 1,157 (24.1)
Severe diabetes 439 (9.1)
Peripheral vascular disease 231 (4.8)
Smoker/smoking history 1,686 (35.1)
INTERMACS profile
1 1,458 (14.7)
2 3,661 (37.0)
3 2,741 (27.7)
4–7 2,034 (20.6)
Blood pressure (mmHg), mean ± SD
Systolic 103.7±16.0
Diastolic 64.3±12.0
MAP 77.6±11.2
Table 1 (continued)
Table 1 (continued)
Baseline characteristics Number (%)
Echocardiography
Aortic regurgitation
None 5,456 (56.7)
Mild 2,467 (25.6)
Moderate 321 (3.3)
Severe 52 (0.5)
Not documented/unknown 1,327 (13.7)
Device strategy
BTT 2,783 (27.1)
Possible BTT, likely* 2,282 (22.2)
Possible BTT, moderate* 1,026 (10.0)
Possible BTT, unlikely* 336 (3.3)
DT 3,783 (36.8)
BTR 54 (0.5)
RT 23 (0.2)
AH use
#
ACE inhibitor 4,939 (47.8)
ARB 1,470 (14.2)
Aldosterone antagonist 5,221 (50.6)
Beta blocker 7,827 (75.8)
CCB NR
Hydralazine NR
Data presented as number (% of patients with available data), 
unless otherwise noted. *, likelihood of becoming eligible 
for transplant listing (not yet listed); 
#
, at time of implantation 
or within the last year. BMI, body mass index; SD, standard 
deviation; INTERMACS, Interagency Registry for Mechanically 
Assisted Circulatory Support; LVEDD, left ventricular end-
diastolic dimension; BTT, bridge to transplant (currently listed 
for transplant); DT, destination therapy; BTR, bridge to recovery; 
RT, rescue therapy; ARB, angiotensin receptor blocker; CCB, 
calcium channel blocker; NR, not recorded by INTERMACS.
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Figure 2 SBP and AH use following continuous-flow left ventricular assist device implantation. MAP, mean arterial pressure; SBP, systemic 
blood pressure; AH, antihypertensive; CI, confidence interval.
Figure 3 SBP following continuous-flow left ventricular assist device implantation, stratified by yearly vital status. MAP, mean arterial 
pressure; SBP, systemic blood pressure. 
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AH requirement (1.9 AHs/patient, 95% CI: 1.89–1.94) was 
unchanged from the pre-implantation baseline. After CF-
LVAD implantation, beta blockers were the most frequently 
used AHs, followed by ACE inhibitors and aldosterone 
antagonists (Figure 4). Beta-blocker, ACE-inhibitor, and 
aldosterone-antagonist utilizations all appeared to increase 
rapidly in the first 3 months post-implant (Figure 4).
The most common AH regimens employed at 1 week, 
1 month, and 3 months of follow-up are shown in Figure 5. 
This analysis was limited to these early time points as most 
of the changes in SBPs and AH utilization occurred with 
the first 3 months after CF-LVAD implantation; 44% 
(n=4,463) of patients required no AHs and 21% (n=2,102) 
were on sole beta blockade at 1 week; by 3 months, only 
10% (n=484) of patients remained off AHs. By that point, 
a plurality of patients were on lone beta-blocker therapy 
(15%, n=720); the next most common regimens at 3 months 
post-implantation were the combination of a beta blocker 
and an ACE inhibitor (14%, n=672) followed by triple-
agent therapy with a beta blocker, an ACE inhibitor, and an 
aldosterone antagonist (11%, n=540) (Figure 5). 
We additionally examined whether implant era played 
any role in AH management, choosing again to focus only 
on early time points (i.e., 1 and 3 months post-implant) 
given that these represented the period of greatest flux in 
both SBPs and medication use (Figure 6). For patients whose 
devices were implanted in 2012, the 1-month frequencies-of-
use of beta blockers, aldosterone antagonists, and angiotensin 
receptor blockers (ARBs) were all significantly higher than 
their respective values in the baseline year of 2008 (62.4% 
vs. 50.5%, P<0.001; 35.6% vs. 25.6%, P=0.003; and 7.1% vs. 
3.6%, P=0.050; respectively). The 1-month frequencies-of-
use of beta blockers and ARBs were also significantly higher 
in 2013, compared again to their respective baseline values 
in 2008 (58.4% vs. 50.5%, P=0.022 and 7.5% vs. 3.6%, 
P=0.032, respectively) (Figure 6, top panel).
The frequencies-of-use of beta blockers and aldosterone 
antagonists were significantly higher in subsequent years 
at the 3-month time point as well: beta blockers 71.8% in 
2011 (P=0.009) and 71.3% in 2012 (P=0.014) vs. 65.3% in 
2008 and aldosterone antagonists 31.1% in 2010 (P=0.007), 
33.7% in 2011 (P<0.001), 36.9% in 2012 (P<0.001), and 
36.4% in 2013 (P<0.001) vs. 24.1% in 2008 (Figure 6, 
bottom panel).
Discussion
This study constitutes the most comprehensive examination 
Figure 4 Frequency of specific AH agents used following continuous-flow left ventricular assist device implantation. AH, antihypertensive; 
ACE, angiotensin-converting-enzyme; CCB, calcium channel blocker; ARB, angiotensin receptor blocker.
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of SBP and AH management in patients supported with 
CF-LVADs. In leveraging the INTERMACS registry, we 
were able to describe blood pressure and medication trends 
representative of the “real-world” experience with this type 
of device, demonstrating that: (I) systemic pressures rose 
quickly following pump implantation and, among long-term 
survivors, stabilized after 3 to 6 months; (II) these early 
changes in blood pressure were matched by concordant 
changes in AH use; and (III) AH utilization increased with 
chronologic year of implantation.
In their analysis of blood pressure control in 96 CF-
LVAD patients, Lampert et al. similarly demonstrated that 
MAPs climbed steadily in response to device implantation 
and that these increases occurred early (within 3 months) 
during the post-implant course (5). Although the authors 
followed a predefined institutional blood pressure protocol 
that set a goal MAP of less than 80 mmHg, their cohort’s 
mean MAP was in excess of this as early as 2 months post-
implantation (5). By 4 months, for example, patients’ MAPs 
averaged near 85 mmHg (5). We found that systemic 
pressures ascended rapidly to rather high levels in our 
study population as well. While we do not know the goal 
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Figure 5 Most common AH regimens employed during the first 3 months following continuous-flow left ventricular assist device 
implantation. AH, antihypertensive; ACE, angiotensin-converting-enzyme.
Figure 6 Frequency of specific AH agents used following continuous-flow left ventricular assist device implantation, stratified by implant 
year. *, P<0.05 (vs. 2008); **, P<0.001 (vs. 2008). AH, antihypertensive; ACE, angiotensin-converting-enzyme; ARB, angiotensin receptor 
blocker.
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pressures the physicians of the patients in our cohort were 
targeting—for reference, the 2013 International Society for 
Heart and Lung Transplantation (ISHLT) MCS guidelines 
recommend a goal MAP of ≤ 80 mmHg (11)—it is obvious 
that patient MAPs were well above what most in the field 
would judge as optimal. Moreover, we cannot definitively 
say whether the observed high mean MAPs in the present 
study were a result of lax treatment or were due to pressures 
that proved intransigent in the face of appropriate AH 
therapy. 
The observation that AH utilization was increasing 
synchronously with increasing systemic pressures suggests 
that clinicians, at least partially, were attempting to 
bring MAPs under control. However, considering that at 
6 months post-implantation patients’ MAPs were over 10% 
higher than pre-implant, one might expect that patients 
would have been on a resultant greater number of AHs 
as well; yet, we observed that patients were actually on 
fewer AH medications at that time point compared to pre-
implantation. Additionally, at 2 years, when patients were 
finally on the same number of medications as they had been 
prior to device implantation, their MAPs were on average 
almost 13% higher than what they had been pre-device—
this suggests that responsiveness to AH medications may 
be reduced in patients following CF-LVAD implantation. 
It is noteworthy that almost half of our cohort was 
INTERMACS 1–2 before LVAD implantation, meaning 
that some of these patients were on AHs for neurohumoral 
modulation of heart failure and not specifically for 
hypertension; however, with that being said, this does not 
change the observation the AH utilization continued to 
synchronously increase with increasing systemic pressures 
after LVAD implantation.
The AH agents and regimens used in managing this 
hypertension also deserve closer attention. The immediate 
3-month period following CF-LVAD implantation was 
notable for both the observed rapid expansion in overall 
AH use and the quick pace with which the frequencies-of-
use of the individual drugs were growing. Naturally, these 
significant early changes in how often certain drugs were 
being used meant that the composition of AH regimens 
also changed markedly during this time period (Figure 5). 
Notably, we did not include an analysis of diuretics in this 
cohort; as the ISHLT only recommends diuretics (class IC) 
if post LVAD implantation patients in the case of volume 
overload and ventricular dysfunction, we chose to exclude 
diuretics in order to avoid further confounding our results 
that aim to focus on blood pressure control. Since there 
are no guidelines that outline which AHs should be used as 
first-line or adjunctive agents in CF-LVAD patients, one 
can only speculate as to the motivations underlying this 
shifting makeup. Ideally, our community would determine 
which AH regimens are most efficacious in these patients 
but this would likely prove statistically challenging in 
the presence of so many confounding time-dependent 
covariates. 
Among the reasons for INTERMACS being such a 
powerful resource is the fact that the registry has captured 
data on almost all CF-LVAD implantations in the US over 
nearly the past decade. Coupling this strength with the 
well-publicized (12) finding that a recent unexpected uptick 
in CF-device thromboses was implant-era dependent led us 
to examine what influence, if any, year of implantation had 
on AH utilization (Figure 6). We noticed that the 1- and 
3-month frequencies-of-use of three AH agents increased 
significantly over time compared to the baseline year of 
2008. Most strikingly, 1-month beta-blocker utilization had 
grown nearly 25% by 2012, while 1-month aldosterone-
antagonist use and ARB use had increased 39% and 97% 
by that year, respectively. It was around this same time—
2011/2012—that the incidence in pump thrombosis was 
noted to be rising (12). However, what effects these era-
dependent increases in AH utilization may have had on 
outcomes was not assessed in the present context and this 
therefore warrants investigation.
Our intention in this descriptive project was to provide 
analyses that were both clinically relevant and widely 
applicable; it is with this in mind that we elected to study 
SBPs in terms of MAPs, regardless of how the pressures 
were obtained (e.g., by automated cuff, traditional 
sphygmomanometry and auscultation, or by Doppler). 
In so doing, we treated the Doppler opening pressure as 
representing the MAP in those patients for whom this 
measurement was available. Doppler pressures have been 
shown to correlate well with MAPs obtained via arterial 
catheters, more accurately reflecting the MAP than the 
systolic blood pressure in patients with CF pumps (13). 
Although Doppler pressures may sometimes overestimate 
true MAPs in cases of preserved pulsatility (14), considering 
that the aforementioned ISHLT guidelines designate ideal 
MAPs (as opposed to goal systolic/diastolic pressures), we 
felt that using MAPs in the present study would be more 
clinically relatable.
Although ours is the largest study yet delving into the 
complex issue of systemic hypertension in patients with 
CF-LVADs, this work does have several limitations. First, 
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INTERMACS does not disclose the subtype (i.e., axial-flow 
versus centrifugal) of the pumps that are implanted; as such, 
we were unable to distinguish between the two in our cohort 
and therefore cannot comment on what effect(s) differences 
in pump design may have had on SBPs. In their analysis, 
though, Lampert et al. found no statistically significant 
differences in mean MAPs among those patients implanted 
with axial-flow versus centrifugal devices over the first 
5 months of support (5). Second, INTERMACS does not 
collect detailed information with respect to the exact agents 
prescribed within a given class of AHs nor does the registry 
capture dosing data; we were thereby further limited in our 
descriptive abilities. Third, anti-hypertensive agents such as 
beta-blockers, aldosterone antagonists and nitrates can be 
used for purposes other than blood pressure control, which 
may have confounded our results. Finally, as most MCS 
specialists would agree, what is ultimately important for 
our community to figure out is determining the impact that 
post-implant systemic pressures have on specific outcomes 
like aortic insufficiency, pump thrombosis, stroke, and 
survival. As alluded to earlier, the kind of longitudinal study 
that could potentially do this using the current data would 
be inherently complex in that it would involve numerous 
intertwined time-dependent covariates. Such covariates, 
of which blood pressure is one, vary with time and (I) can 
influence other measured variables (which themselves may 
change over time, like aortic regurgitation), and (II) may 
change in response to one or more of these other measured 
variables (15). Hence, in the present study, it was not our 
goal to answer the question: “how does systemic hypertension 
at any point in time after CF-LVAD implantation affect 
outcome X?”
Conclusions
SBP rises rapidly following CF-LVAD implantation, 
often in excess of currently accepted norms, resulting in 
concomitant increases in AH use—use that has grown over 
consecutive implant years. Despite this ever-increasing 
utilization, responsiveness to AH medications may be 
reduced in patients following CF-LVAD implantation. The 
descriptions provided herein should catalyze research on the 
role of SBP in determining clinical outcomes for patients 
with CF pumps.
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